Guanidines (i.e., N=c(-n)-n) Patents (Class 514/634)
  • Patent number: 11285167
    Abstract: The present invention disclosed herein provides synergistic nutritional neuroprotective compositions for ameliorating neural dysfunction. Particularly, the invention relates to synergistic, efficient, nutritional composition for comprising specific combination of decarboxylated L-arginine called agmatine sulphate and nicotinamide riboside chloride, wherein agmatine sulphate and nicotinamide riboside chloride are present in the weight ratio of 1:0.05 to 1:2 along with pharmaceutically acceptable excipients. More particularly, the present invention offers synergistic effect for ameliorating neural dysfunction encompasses cerebrovascular diseases, neurodevelopmental disorders, mood disorders, mental health disorders and like thereof.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: March 29, 2022
    Assignee: CELAGENEX RESEARCH (INDIA) PVT. LTD.
    Inventors: Jotiram Palkar, Rajendra Prasad Tongra
  • Patent number: 11007187
    Abstract: The invention concerns a medicine and a prophylactic medicine for COVID-19 disease. The inventive medicine targets the endosomic, non-endosomic and/or intracellular viral pathways and inhibits them. The best mode of the invention is considered to be the medicine that blocks all three viral pathways. In the best mode the individual dose of a constituent component of the medicine is arranged to a dosage size sufficient to inhibit its designated SARS-CoV-2 viral pathway. This allows the dose of a particular pharmacological agent to be smaller than in a drug with just one kind of pharmacological agent. The best mode of the invention shuts the two cell membrane viral pathways and the one intracellular viral pathway with the minimum efficient dose, thereby preventing drug overdose, and enabling prophylactic or preventive use.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: May 18, 2021
    Assignee: THERAPEUTICA BOREALIS OY
    Inventors: Kalervo Väänänen, Lauri Kangas, Matti Rihko
  • Patent number: 10172817
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: January 8, 2019
    Assignee: The Rockefeller University
    Inventors: Sohail Tavazoie, Jia M. Loo
  • Patent number: 10100148
    Abstract: The present invention provides specific alkoxylation products, a process for preparing them, compositions which comprise these alkoxylation products, and the use thereof.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: October 16, 2018
    Assignee: Evonik Degussa GmbH
    Inventors: Eva Emmrich-Smolczyk, Olga Fiedel, Mladen Vidakovic
  • Patent number: 9827210
    Abstract: A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: November 28, 2017
    Assignee: Phovitreal Pty Ltd
    Inventor: Gregory Lynn Willis
  • Patent number: 9555016
    Abstract: Agents and methods are provided for breaking down and/or assisting in the removal of clots, in embodiments chronic clots, from the vasculature. In embodiments, the agents and methods may be used in the vasculature, in particular the peripheral venous vasculature, in order to prevent clot formation and/or lyse clots in patients suffering from complications, such as thrombosis, or from conditions, such as deep vein thrombosis (DVT).
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: January 31, 2017
    Assignee: Covidien LP
    Inventor: Jennifer Makridakis
  • Patent number: 9314526
    Abstract: Compositions and methods for treating disordered tissues, such as caused by pathogens and/or by toxins. The treatment compositions include an anti-infective active agent, a liquid carrier, and benzocaine in an amount so that the treatment composition penetrates more quickly into disordered tissue compared to the treatment composition in the absence of the benzocaine. In addition, the benzocaine can increase residence time of the anti-infective active in the treatment area. The preferred anti-infective active agent can be an organohalide, such as a quaternary ammonium halide compound, an example of which is benzalkonium chloride. The treatment compositions and methods may employ the use of an applicator adapted for use in promoting penetration of the treatment composition and/or agitation of the disordered tissue to further enhance penetration.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: April 19, 2016
    Assignee: QUADEX PHARMACEUTICALS, LLC
    Inventors: B. Ron Johnson, James P. McCarthy
  • Patent number: 9125954
    Abstract: The present invention provides a method for the synthesis of 18F-labelled biomolecules, which is amenable to automation. The present invention also provides a cassette for automating the method of the invention. The method of the present invention provides numerous advantages over the prior art methods. One less purification step is required as compared with known methods. Also, one less reagent is required as a particular reagent is employed in two different steps. The chemistry process is thereby simplified, the cost of goods is reduced and the burden of validation and documentation of reagents required for GMP clinical production is minimized.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: September 8, 2015
    Assignee: GE Healthcare Limited
    Inventors: Rajiv Bhalla, Anthony Wilson, Imtiaz Khan, Janne Brown
  • Publication number: 20150093365
    Abstract: Provided herein are compositions containing photoactivatable caged tamoxifen and tamoxifen derivative molecules. Also provided are kits containing one of these compositions and a light source. Also provided are methods of optically inducing nuclear translocation of a fusion protein containing a mammalian estrogen receptor ligand binding domain in a eukaryotic cell and methods of optically inducing recombination in a eukaryotic cell that include contacting a eukaryotic cell with at least one of these compositions. Also provided are methods of treating breast cancer in a subject that include administering a photoactivatable caged tamoxifen or tamoxifen derivative molecule to a subject having breast cancer.
    Type: Application
    Filed: March 14, 2013
    Publication date: April 2, 2015
    Inventors: Xin Lu, Sarit S. Agasti, Ronald A. DePinho, Ralph Weissleder
  • Publication number: 20150086523
    Abstract: The invention is dietary supplements, nutraceutical compositions, medical foods, and animal feeds that have cytoprotective (cell and tissue protection) and health promoting effects. The compositions contain a high dose range of agmatine and nutraceutical acceptable salts thereof as dietary fortification for providing effective long-term cytoprotection and affording for soft stool. The compositions may contain agmatine alone or in combination with other dietary ingredients having health promoting effects. The compositions can be prepared with dietary accepted excipients and compatible forms of carriers, including but not limited to, powders, tablets, capsules, controlled release carriers, lozenges and chewable preparations, liquid suspensions, suspensions in an edible supporting matrix or foodstuff and oral rehydration solutions, to enable consumption of said compositions.
    Type: Application
    Filed: December 1, 2014
    Publication date: March 26, 2015
    Inventors: Gad Gilad, Varda Gilad
  • Publication number: 20150056305
    Abstract: Provided are dithiol mucolytic agents. These agents increase the liquefaction of mucus in a patient with excessive mucus or mucus with increased viscoelastic, cohesive, or adhesive properties. Also provided are a variety of methods of treatment using these inventive mucolytic agents.
    Type: Application
    Filed: August 13, 2014
    Publication date: February 26, 2015
    Applicant: PARION SCIENCES, INC.
    Inventors: Michael R. Johnson, William R. Thelin, Ronald A. Aungst, JR.
  • Publication number: 20150051291
    Abstract: A composition and method of treating stroke by administration of a novel sigma agonist is presented. Twenty-four hours after MCAO, systemic administration of several novel sigma agonists including: Bromo-DTG; Chloro-DTG; N,N?-di-1-Naphthylguanidine hydrochloride (NAGH); N,N?-di-p-Nitrophenylguanidine HCL (NAD) or vehicle were injected subcutaneously daily for 3 days. Rats treated with Bromo-DTG and Chloro-DTG had no significant improvements in any of the motor or cognitive tests while NAGH treated rats showed improved vertical movement and had significantly less motor asymmetry and bias than vehicle treated rats. Sigma receptor agonist NAGH also was found to exert its long-term neuroprotective effects by preserving both gray matter and white matter tracts.
    Type: Application
    Filed: November 3, 2014
    Publication date: February 19, 2015
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Keith R. Pennypacker, Alison Willing, Javier Cuevas, Jon C. Antilla, Michelle Cortes-Salva
  • Publication number: 20150051161
    Abstract: The present invention provides compositions and methods for detecting carboxymethyl-lysine (CML) and circulating receptor for advanced glycation end (RAGE) products, and methods for correlating CML and RAGE levels with age-related disease. In particular, serum CML and/or circulating receptor for advanced glycation end (RAGE) products can be used as a clinical biomarker in diagnostics to identify people who are at a higher risk of developing adverse ageing-related outcomes.
    Type: Application
    Filed: April 10, 2014
    Publication date: February 19, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Richard David Semba, Luigi Ferruci, Edward G. Lakatta
  • Patent number: 8946299
    Abstract: A product comprising a calixarene for its use in the treatment of pathologies involving at least one bacterial strain having a resistance to at least one defined antibiotic, on patients undergoing simultaneous or sequential treatment with a given antibiotic to which said bacterial strain optionally has a resistance.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: February 3, 2015
    Assignee: Universite de Lorraine
    Inventors: Marion Grare, Raphaël Emmanuel Duval
  • Publication number: 20150031738
    Abstract: The present invention provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative.
    Type: Application
    Filed: December 10, 2012
    Publication date: January 29, 2015
    Applicant: University of Massachusetts
    Inventors: Yan Li, Hitest Thaker, Gregory N. Tew, Dahui Liu, Wenxi Pan
  • Publication number: 20150031635
    Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
    Type: Application
    Filed: June 30, 2014
    Publication date: January 29, 2015
    Inventors: Thomas E. Jenkins, Julie D. Seroogy, Jonathan W. Wray
  • Publication number: 20150018293
    Abstract: Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.
    Type: Application
    Filed: May 12, 2014
    Publication date: January 15, 2015
    Applicant: NEWMARKET PHARMACEUTICALS LLC
    Inventors: David ROCK, Mark RIDALL
  • Patent number: 8933122
    Abstract: Cationic surfactants derived from the condensation of fatty acids and esterified dibasic amino acids, such as from lauric acid and arginine, in particular the ethyl ester of the lauramide of the arginine monohydrochloride (LAE), may be used for the treatment of objects which are infected with spores. The spores may originate from bacteria or fungi.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: January 13, 2015
    Assignee: Laboratorios Miret, S.A.
    Inventors: Xavier Rocabayera Bonvila, Sergi Figueras Roca, Roger Segret Pons, Eva Piera Eroles
  • Publication number: 20150011559
    Abstract: The invention provides methods of treating a bacterial infection in a mammal comprising administering to the mammal a compound of formula I: wherein A, B, and X have any of the meanings defined in the specification; or a pharmaceutically acceptable salt thereof, as well as novel compounds of formula I and salts thereof and pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 11, 2013
    Publication date: January 8, 2015
    Inventors: Edmond J. LaVoie, Ajit Parhi, Daniel S. Pilch, Yongzheng Zhang, Malvika Kaul
  • Publication number: 20150005387
    Abstract: The present invention relates to novel compositions including a mixture of cadaverine, putrescine, spermine and spermidine at a concentration ranging from 0.31 to 0.63 nmol per gram of composition, the composition also including agmatine at a concentration ranging from 120 to 17100 nmol per gram of composition, and uses thereof in the treatment, in a patient, of pathologies associated with cellular hyperproliferation.
    Type: Application
    Filed: January 10, 2013
    Publication date: January 1, 2015
    Applicant: NUTRIALYS MEDICAL NUTRITION SA
    Inventor: Jacques-Philippe Moulinoux
  • Patent number: 8916613
    Abstract: The invention relates to insecticide mixtures comprising thiodicarb and at least one other known active ingredient from the category of chloronicotinyls, as well as the use of these mixtures to control animal pests.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: December 23, 2014
    Assignee: Bayer CropScience AG
    Inventors: Wolfram Andersch, Heike Hungenberg, Wolfgang Thielert
  • Patent number: 8916612
    Abstract: The invention is dietary supplements, nutraceutical compositions, medical foods, and animal feeds that have cytoprotective (cell and tissue protection) and health promoting effects. The compositions contain a high dose range of agmatine and nutraceutical acceptable salts thereof as dietary fortification for providing effective long-term cytoprotection and affording for soft stool. The compositions may contain agmatine alone or in combination with other dietary ingredients having health promoting effects. The compositions can be prepared with dietary accepted excipients and compatible forms of carriers, including but not limited to, powders, tablets, capsules, controlled release carriers, lozenges and chewable preparations, liquid suspensions, suspensions in an edible supporting matrix or foodstuff and oral rehydration solutions, to enable consumption of said compositions.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: December 23, 2014
    Inventors: Gad Gilad, Varda Gilad
  • Publication number: 20140371252
    Abstract: Processes for making and using compounds of formula (I): wherein R1, R2, R3, R4a, R4b, R5 and R6 are defined herein, as well as other indene derivatives are disclosed herein. These compounds are disclosed as being useful in treating inflammatory conditions or diseases.
    Type: Application
    Filed: January 23, 2014
    Publication date: December 18, 2014
    Applicant: Aquinox Pharmaceuticals Inc.
    Inventors: Jeffery R. Raymond, Kang Han, Yuanlin Zhou, Yuehua He, Bradley Noren, James Gee Ken Yee
  • Publication number: 20140364505
    Abstract: Agents and methods are provided for breaking down and/or assisting in the removal of clots, in embodiments chronic clots, from the vasculature. In embodiments, the agents and methods may be used in the vasculature, in particular the peripheral venous vasculature, in order to prevent clot formation and/or lyse clots in patients suffering from complications, such as thrombosis, or from conditions, such as deep vein thrombosis (DVT).
    Type: Application
    Filed: June 10, 2013
    Publication date: December 11, 2014
    Inventor: Jennifer Makridakis
  • Patent number: 8889163
    Abstract: Facially amphiphilic polyphenylene and heteroarylene polymers and articles made therform having biocidal surfaces are disclosed. The polymers can inhibit the growth of microorganisms in contact with the surface or in areas adjacent to said biocidal surface. There is also disclosed a methods to attach facially amphiphilic polmers to a solid support. Utility as a contact disinfectant is disclosed.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: November 18, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: William F. DeGrado, Gregory N. Tew, Michael L. Klein
  • Publication number: 20140322304
    Abstract: Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described. Methods for treatment of pathological conditions particularly cancer, in a subject using one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described herein.
    Type: Application
    Filed: July 10, 2014
    Publication date: October 30, 2014
    Inventors: Gavin P. Robertson, Raghavendra Gowda Chandagalu D., Subbarao V. Madhunapantula, Gajanan S. Inamdar, Omer F. Kuzu
  • Publication number: 20140308317
    Abstract: The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; killing or inhibiting the growth of a Plasmodium species; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative.
    Type: Application
    Filed: December 9, 2013
    Publication date: October 16, 2014
    Applicant: CELLCEUTIX CORPORATION
    Inventors: Xiaodong Fan, Yongjiang Xu, Dahui Liu, Michael J. Costanzo
  • Patent number: 8858991
    Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: October 14, 2014
    Assignee: Pathologica LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Publication number: 20140303101
    Abstract: This invention pertains to dental care compositions with antimicrobial benefits. In particular, the invention provides for compositions of oral tissue-adherent salts that release biocidal ions on a controlled release basis and thereby provide and maintain an essentially uniform concentration of biocidal ions above the MBC or MIC of the target bacteria at the site of application in the mouth for an extended period of time. The compositions are useful for treating or preventing oral diseases resulting from bacteria, fungal or yeast infections, such as caries, gingivitis, periodontal disease and candidiasis.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 9, 2014
    Inventors: Anthony Errol Winston, Richard F. Stockel, Anthony Joseph Sawyer
  • Patent number: 8840876
    Abstract: An antimicrobial composition comprising: a complex of an anionic polyester with an antimicrobial cationic surfactant, wherein the anionic polyester has at least one carboxylic group. A medical device having an antimicrobial composition comprising: a complex of an anionic polyester with an antimicrobial cationic surfactant wherein the anionic polyester has at least one carboxylic group.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: September 23, 2014
    Assignee: Ethicon, Inc.
    Inventors: Modesto Eemeta, Robert Di Luccio, Xintian Ming
  • Publication number: 20140228388
    Abstract: Provided herein are phenyl-guanidine derivatives for the inhibition of Rac1 which blocks its interaction with guanosine exchange factors (GEFs) belonging to the DBL family as agents for the treatment of aggressive and/or resistant tumours, as well as pharmaceutical compositions comprising them, their use in therapy and processes for their preparation.
    Type: Application
    Filed: October 10, 2012
    Publication date: August 14, 2014
    Applicants: Universidad Nacional de Quilmes, Chemo Research, S.L.
    Inventors: Pablo Lorenzano Menna, Julieta Comín, Daniel Eduardo Gómez, Daniel Fernando Alonso
  • Publication number: 20140223609
    Abstract: Embodiments of the present invention relate to insecticidal Bacillus thuringiensis Cry1 and Cry2 polypeptides. Methods for using the polypeptides and nucleic acids of embodiments of the invention to synergistically enhance resistance of plants to insect predation are encompassed in embodiments of the present invention.
    Type: Application
    Filed: April 16, 2014
    Publication date: August 7, 2014
    Applicants: E I DU PONT DE NEMOURS AND COMPANY, PIONEER HI BRED INTERNATIONAL INC
    Inventors: John Lindsey Flexner, Deirdre Kapka-Kitzman, Lisa Procyk, Bruce H. Stanley, Jianzhou Zhao
  • Publication number: 20140206629
    Abstract: The invention relates to inhibition of SDF-1? expression in subacromial bursa cells by CXCR-4 inhibitors. Bursal cell migration in response to SDF-? stimulation is also decreased in the presence of CXCR4 inhibitors. Accordingly, provided are methods for treating or ameliorating a musculoskeletal disorder.
    Type: Application
    Filed: February 17, 2012
    Publication date: July 24, 2014
    Applicant: RHODE ISLAND HOSPITAL
    Inventor: Theodore A. Blaine
  • Publication number: 20140193503
    Abstract: The invention concerns a suspension concentrate comprising, expressed by weight based on the total weight of the composition: a) 40 to 80% particles of dodecylguanidine or an acid salt of dodecylguanidine of the structure (1), wherein X represents an acid residue of a monocarboxylic, dicarboxylic or a mineral acid, b) 0 to 10% of an anti-freeze compound, c) 1 to 10% of a wetting agent and/or d) a dispersing agent, e) 0 to 5% of an antifoaming agent, f) remainder water characterized in that, the median diameter of the particles (d50) is at least 7 ?m and below 40 ?m; and its use for the treatment of a fungicidal disease on crops or ornamental plants.
    Type: Application
    Filed: August 22, 2012
    Publication date: July 10, 2014
    Applicant: AGRIPHAR S.A.
    Inventor: Alan Pirotte
  • Publication number: 20140141098
    Abstract: Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal or based on a synchronous parameter of the mammal's respiratory cycle. Varying therapeutic profiles may be used for the delivery of gaseous nitric oxide depending on the severity of the excess mucus accumulation. Parameters for the therapeutic profiles may include flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways.
    Type: Application
    Filed: August 26, 2013
    Publication date: May 22, 2014
    Applicant: Pulmonox Technologies Corporation
    Inventors: Bruce R. Murray, Christopher C. Miller, Douglas R. Hole
  • Patent number: 8716530
    Abstract: The present invention discloses methods of use of facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers, including, but not limited to, pharmaceutical uses of the polymers and oligomers as antimicrobial agents and as antidotes for hemorrhagic complications associated with heparin therapy. The present invention also discloses novel facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers, compositions of the novel polymers and oligomers, including pharmaceutical compositions, and methods of designing and synthesizing the facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: May 6, 2014
    Assignee: The Trustess of the University of Pennsylvania
    Inventors: William F. DeGrado, Dahui Liu, Gregory N. Tew, Michael L. Klein
  • Publication number: 20140121172
    Abstract: Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis, which is the % of glucose production that comes from gluconeogenesis (“GNG”), as opposed to glycogenolysis (“GLY”), the other form of glucose production. Nutritional formulations, materials, cocktails and methods for feeding patients by parenteral and other means are disclosed. The amount, type and rate of such nutritional feeding are typically based upon the above estimating. The invention discloses formulations that contain labels, such as deuterium, for medical diagnostics, such as for estimating BES and fractional gluconeogenesis.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 1, 2014
    Applicant: Run Them Sweet, LLC
    Inventors: Michael A. Horning, George A. Brooks
  • Publication number: 20140121193
    Abstract: The invention provides methods for treating or ameliorating cognitive dysfunction, fatigue, energy, concentration, mood, and pain associated with fibromyalgia using compositions containing methylphenidate or pharmaceutically equivalents thereof.
    Type: Application
    Filed: November 1, 2013
    Publication date: May 1, 2014
    Inventors: Robert S. KATZ, Frank LEAVITT
  • Patent number: 8703825
    Abstract: Novel compounds of the following formula (I): in which: n represents an integer from 1 to 12, in particular from 1 to 8, m and m? represent, independently of one another, integers from 0 to 8, q and q? represent, independently of one another, integers from 0 to 2, p and p? represent, independently of one another, integers from 0 to 4, A and A? represent, independently of one another, a CH2 group, (particular case of amidines) an NH group or an NR? group, in which R? is a linear or branched alkyl group with 1 to 3 carbon atoms, B and B? represent, independently of one another, an oxygen atom or a CH2 group, R and R? are, independently of one another, a halogen, such as chlorine, bromine, iodine or fluorine atoms, or a linear or branched alkyl group with 1 to 3 carbon atoms, use thereof as medicaments and the method of preparation thereof.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: April 22, 2014
    Assignee: Universite de Lorraine
    Inventors: Raphaël Emmanuel Duval, Marion Grare, Maxime Mourer, Jean-Bernard Regnouf-De-Vains
  • Publication number: 20140088198
    Abstract: Agrochemical compositions are described which contain a carboxylic acid salt of dodecylguanidine and a compatibility agent for slowing down the dissociation reaction of the carboxylic acid salt of dodecylguanidine in an aqueous medium. Also, the formation of anionic dodecylguanidine is suppressed or prevented. The ratio of the dodecylguanidine acetate to that of the compatibility agent in the agricultural compositions is below 5.0, preferably between 3.0 and 0.5, more preferably equals 1.4.
    Type: Application
    Filed: May 10, 2011
    Publication date: March 27, 2014
    Applicant: AGRIPHAR S.A.
    Inventor: Alan Pirotte
  • Publication number: 20140066517
    Abstract: A product comprising a calixarene for its use in the treatment of pathologies involving at least one bacterial strain having a resistance to at least one defined antibiotic, on patients undergoing simultaneous or sequential treatment with a given antibiotic to which said bacterial strain optionally has a resistance.
    Type: Application
    Filed: April 11, 2012
    Publication date: March 6, 2014
    Inventors: Marion Grare, Raphaël Emmanuel Duval
  • Publication number: 20140051712
    Abstract: The invention describes pharmaceutical agents capable of crossing the blood brain barrier to protect against organophosphate pesticides and nerve agents or other electrophiles by reactivating inhibited cholinesterase (i.e., acetylcholinesterase and butyrylcholinesterase) and other proteins in the peripheral and central nervous system.
    Type: Application
    Filed: December 16, 2011
    Publication date: February 20, 2014
    Inventors: John R. Cashman, Jarosiaw Kalisiak
  • Patent number: 8642659
    Abstract: The invention relates to ether guanidines of the general formulae (I) and/or salts or hydrates thereof, in which R1=—CH2—CH2—CH2—O—R3 where R3 is, independently of the others, hydrocarbon radicals having greater than or equal to 10 carbon atoms, where part of the ether guanidines has radicals R3 which are branched and part of the ether guanidines has radicals R3 which are unbranched, and R2=independently of the others H or an optionally branched, optionally double-bond-containing hydrocarbon radical having 1 to 30 carbon atoms, and use thereof in hair treatment compositions and hair aftertreatment compositions, in particular for preventing damage by chemical treatment compositions and for repairing hair which is already damaged.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: February 4, 2014
    Assignee: Evonik Goldschmidt GmbH
    Inventors: Oliver Springer, Peter Muss, Burghard Gruening, Ursula Maczkiewitz, Mike Farwick, Peter Lersch
  • Patent number: 8642278
    Abstract: The disclosed modulators of Rb:Raf-1 interactions are potent, selective disruptors of Rb:Raf-1 binding, with IC50 values ranging from 80 nM to 500 nM. Further, these compounds are surprisingly effective in inhibiting a wide variety of cancer cells, including osteosarcoma, epithelial lung carcinoma, non-small cell lung carcinoma, three different pancreatic cancer cell lines, two different glioblastoma cell lines, metastatic breast cancer, melanoma, and prostate cancer. Moreover, the disclosed compounds effectively disrupt angiogenesis and significantly inhibited tumors in nude mice derived from human epithelial lung carcinoma tumors. Accordingly, the disclosed compounds, pharmaceutical compositions comprising the compounds, methods of inhibiting cell proliferation, methods of treating subjects with cancer, and methods of preparing the disclosed compounds are provided.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: February 4, 2014
    Assignee: University of South Florida
    Inventors: Said M. Sebti, Srikumar Chellappan, Nicholas James Lawrence
  • Publication number: 20130345175
    Abstract: A method for determining the levels of biomarkers, specifically, advanced glycation end products (AGEs) and oxidation products (Ops) in a biological sample such as a plasma ultrafiltrate, is used to determine a patient's risk and/or rate of developing diabetes related nephropathy. The preferred biomarkers to measure include N?-(1-carboxyethyl-lysine (CEL), methylglyoxyl-derived hydroimidazolone (MGHI) and N?-carboxymethyllysine (CML). Also provided herein is a method of diabetic care which includes determining a diabetic patient's risk of developing diabetes related kidney disease and adjusting the patient's treatment regimen to include in addition to glucose lowering agents, additional treatments such as medications that modify the renin-angiotensin system, or specialized diets with low levels of AGEs or oxidative products.
    Type: Application
    Filed: June 10, 2013
    Publication date: December 26, 2013
    Inventor: Paul J. Beisswenger
  • Patent number: 8609735
    Abstract: The present invention provides a rapid-acting, blood arginine level-increasing oral preparation containing citrulline or a salt thereof and arginine or a salt thereof as active ingredients. The rapid-acting, blood arginine level-increasing oral preparation of the present invention can rapidly and effectively increase blood arginine level after ingestion, and can rapidly provide an arginine ingestion effect.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: December 17, 2013
    Assignees: Kyowa Hakko Bio Co., Ltd., National University Corporation Nagoya University
    Inventors: Masayuki Ochiai, Koji Morishita, Toshio Hayashi
  • Patent number: 8604073
    Abstract: An antimicrobial composition comprising (a) a cationic surfactant derived from the condensation of fatty acids and esterified dibasic amino acids, such as lauric arginate and (b) an antibiotic, such as of ?-lactam antibiotics, polypeptides, quinolones. The composition may be used as a stand alone antimicrobial formulation, or in combination with medical articles or medical devices.
    Type: Grant
    Filed: March 27, 2006
    Date of Patent: December 10, 2013
    Assignee: Ethicon, Inc.
    Inventors: Xintian Ming, Stephen J. Rothenburger
  • Patent number: 8604065
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, and use for treating cancer thereof are disclosed, wherein, the definitions of X, Y, R1, R2 and n are described in description.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: December 10, 2013
    Inventors: Hesheng Zhang, Xin Chen, Yingwei Chen, Junjie Cong, Xingwen Li
  • Publication number: 20130315982
    Abstract: A liposomal drug composition comprising: a dimeric or polymeric guanidine derivative or a pharmaceutically acceptable salt thereof as drug substance, and a lipid modified by polyethylene glycole (PEG). The drug composition have cytostatic and antimicrobial activity.
    Type: Application
    Filed: October 28, 2011
    Publication date: November 28, 2013
    Applicant: MINDINVEST HOLDINGS LTD.
    Inventors: Oskar Schmidt, Andreas Wagner, Barbara Rupp-Stanschitz
  • Publication number: 20130317457
    Abstract: The present invention is directed to an aqueous pharmaceutical composition, particularly an aqueous ophthalmic composition, suitable as an injection, particularly an intravitreal injection. The composition includes a biologic therapeutic agent (e.g., an isolated monoclonal antibody that specifically binds to a C5 protein) that tends to raise the viscosity of the composition and a guanidine and/or guanidine derivative (e.g., L-arginine) that tends to lower the viscosity of the composition.
    Type: Application
    Filed: May 23, 2013
    Publication date: November 28, 2013
    Inventors: David Schmitt, Hans-Joachim Wallny